for changes in state and area distributions of sex, age, and race/ ethnicity. Linear and quadratic trends over time were included in the models. Nonsignificant quadratic terms were dropped from the final models. Quadratic trends indicated a significant but nonlinear trend in smoking prevalence over time. †
Current Cigarette Smoking
In 2007, the median prevalence of adult current smoking in the 50 states and DC was 19.8% (Table 1) . Among states, current smoking prevalence was highest in Kentucky (28.3%), West Virginia (27.0%), and Oklahoma (25.8%); and lowest in Utah (11.7%), California (14.3%), and Connecticut (15.5%). Smoking prevalence was 8.7% in USVI, 12.2% in PR, and 31.1% in Guam. Median smoking prevalence among the 50 states and DC was 21.3% (range: 15.5%-28.8%) for men and 18.4% (range: 8.0%-27.8%) for women. Men had a significantly higher prevalence of smoking than women in 30 states, DC, and all three territories.
Trends in Cigarette Smoking
During 1998-2007, linear decreases were observed in 28 states, DC, and PR (Table 2) . Nonlinear trends were detected in 19 other states. Trends in smoking prevalence varied among these states; however, all had reached a peak prevalence before 2004 and then began to decrease. Among 16 of these 18 states, logistic regression models indicated that the prevalence decreased during 1998-2007; in the other two states no change in prevalence occurred. No change over time in smoking prevalence (quadratic or linear) was observed in Alabama, Arizona, Tennessee, and West Virginia. States varied substantially in current levels of smoking and in trends in smoking during 1998-2007. These variations might be attributed to a number of factors, including differences in population demographics, differing levels of tobacco control programs and policies, and variations in tobacco industry marketing and promotion (5) . As part of CDC's National Tobacco Control Program, all states work to implement comprehensive tobacco control programs that include effective strategies for preventing smoking initiation and increasing cessation. § These programs contribute to reductions in smoking prevalence through increases in the unit price of tobacco products, sustaining media campaigns (e.g., encouraging cessation and preventing initiation), implementation of smoke-free policies, support for quitlines, and reduced patient costs for tobacco use treatment (6) . State per-capita tobacco control program expenditures are one measure of the state's ability to implement effective tobacco control program components (6); during 1985-2003, states with higher expenditures had greater overall reductions in adult smoking prevalence (5) .
The findings in this report are subject to at least six limitations. First, smoking prevalence might be underestimated because BRFSS does not survey persons in households without any telephone service (2.5%) or with wireless-only telephones (17.5%), and adults with wireless-only service are more likely (30.2%) than the rest of the U.S. population to be current smokers (7) . Second, estimates for cigarette smoking are based on self-report and are not validated by biochemical tests. However, self-reported data on current smoking status have high validity (8) . Third, the median response rate was 59.1% (range: 32.5%-76.7%) in 1998 and 50.6% (range: 26.8%-65.4%) in 2007. Lower response rates increase the potential for response bias, which could have affected the assessment of trends over time; however, BRFSS aggregated state estimates previously have been shown to be comparable to smoking estimates from other surveys with higher response rates (8) . The 2007 median smoking rate of 19.8% reported in this analysis is the same as the national estimate of cigarette smoking reported from the 2007 National Health Interview Survey (19.8%) (2) . Fourth, trend analyses for Guam and USVI could not be reported because data were not available for the full time span. Fifth, modeling was limited to linear and quadratic trends. However, examination of plots of predicted versus observed prevalence estimates showed that the models fit the data well for the majority of states. For some states, prevalence estimates indicate declines in smoking prevalence might have leveled off since 2005 (Table 2) ; future trend modeling might need to account for this emerging pattern. Finally, only trends in overall current cigarette smoking prevalence were examined; trends might vary among demographic subpopulations within a state. For example, national trends in current smoking prevalence have varied between non-Hispanic white and black women; cigarette use among these two populations was comparable in the mid-1990s, but use declined more rapidly among non-Hispanic black women than non-Hispanic white women during 2000 and 2001 (9) . Assessing trends among subgroups is important for targeting interventions to those most at risk.
Despite declines in smoking prevalence during 1998-2007, cigarette smoking continues to cause large numbers of deaths each year across all states (1) . From 2002 to 2005, states cut funding for tobacco prevention and cessation programs by 28% (approximately $200 million) (10) . In fiscal year 2009, no state is funding comprehensive tobacco control programs at CDC-recommended funding levels, and only nine states are funding at least half of the recommended amount (6, 10) . In contrast, tobacco industry marketing expenditures nearly doubled from 1998 ($6.9 billion) to 2005 ($13.4 billion) (10) . IOM concluded that substantial and enduring reductions in tobacco use depend on federal and state government steps to increase excise taxes, enact bans on smoking in public spaces, and increase health-care coverage for effective cessation interventions. IOM also called for full implementation of comprehensive tobacco control programs at CDC-recommended funding levels (4).
On April 1, 2009, the single largest federal tobacco excise tax increase in history will go into effect, raising the excise tax for cigarettes to $1.01 from the current rate of $0.39. This increase likely will prompt some smokers to make a quit attempt (4) (5) (6) In December 2004, the index patient, an unemployed adult with a history of excessive alcohol and illicit drug use and unstable housing arrangements (i.e., living with various friends and family members), was first evaluated in a local emergency department for cough, hemoptysis, fever, fatigue, and night sweats of 1-month duration. Acid fast-bacilli (AFB) smear-positive, cavitary TB was diagnosed, and the patient began standard treatment with the four first-line TB drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) (5). Initial drug-susceptibility testing (DST) on an isolate from the patient indicated the patient's TB strain was susceptible to all first-line drugs.
The patient initially agreed to receive directly observed therapy (DOT), a mainstay of TB treatment in which patients are observed to ingest each dose of medication to maximize the likelihood of completion of therapy (5 A contact investigation conducted during December 2004-January 2005, after the patient's disease was first diagnosed, included five household contacts, all of whom had negative initial tuberculin skin test (TST) results. A second round of skin testing was planned for 8-10 weeks after the initial round (2) . Despite numerous attempts by health department staff members, four household contacts, including the patient's parent, declined a second evaluation. The one contact who was retested (with the permission of an adult in the home), the patient's child, had a second negative TST result in April 2005.
In April 2005, the index patient began picking up TB medications at the health department each month. The patient's AFB sputum smear test results were negative for the first time, but became positive again by June; DOT was not enforced during this period. From initial diagnosis through June 2005, the index patient's sputum specimens remained culture positive.
During July-December 2005, the patient again was lost to follow-up and received no treatment for TB. In January 2006, the patient returned to the health department with cough and malaise. At that time, the patient's radiographs showed worsening cavitary disease; the AFB sputum smear result was positive, and DST still indicated drug-susceptible TB. The patient was restarted on isoniazid, rifampin, and pyrazinamide but did not comply with DOT. In September 2006, DST results on an M. tuberculosis isolate collected from the index patient in July 2006 indicated MDR TB (i.e., resistance to isoniazid and rifampin). The isolate was susceptible to pyrazinamide, ethambutol, streptomycin, ciprofloxacin, kanamycin, ethionamide, cycloserine, and capreomycin. The patient was prescribed an MDR TB treatment regimen of ethambutol, pyrazinamide, moxifloxacin, and streptomycin. However, in December 2006, the patient's sputum remained AFB smear positive and culture positive for MDR TB, despite consistently taking prescribed medication via DOT during September-December 2006, according to clinic records.
In December 2006, a parent of the index patient died from unrecognized TB meningitis. The otherwise healthy parent had reported chronic headaches and lower back pain during the fall of 2006, progressing to weight loss, fatigue, and general debilitation; human immunodeficiency virus serologies were not tested. Mycobacteria culture results were not available until after the parent's death. Cerebrospinal fluid cultures revealed M. tuberculosis with a genotype that matched that of the index patient. DST results on the parent's isolate indicated drugsusceptible TB, suggesting that transmission from the index patient had occurred before July 2006, when the index patient was first known to have MDR TB. After the parent's culture and autopsy results became available, the health department decided to revisit and intensify the investigation of the index patient's contacts, focusing on family members because the index patient remained unwilling to name social contacts.
In February 2007, a young relative of the index patient who spent considerable time in the same house (not the patient's child), had a positive TST result (25 mm induration). The child was asymptomatic, and a chest radiograph showed left hilar lymphadenopathy, which was not interpreted as TB. No medications were started, and the child was scheduled to return 2-3 weeks later for reevaluation. Six weeks later, this young patient was hospitalized for cough, fever, night sweats, and weight loss. The child's chest radiographs were consistent with TB pneumonia; sputum smear results were AFB negative. A sputum culture was positive for MDR TB, suggesting that the young relative had been infected by the index patient after July 2006, when the index patient was first known to have MDR TB.
Because of the death and pediatric MDR TB diagnosis associated with the index patient's TB, in August 2007 the health department invited MDCH and CDC to assist in its investigation of the other cases in this genotype cluster. During December 2004-April 2007, in addition to the index patient and the two relatives, five other patients had matching genotypes ( Table 1) . Three of the five had drug-susceptible TB: a known social contact of the index patient and two persons with unconfirmed social contact who frequented the same neighborhood. The other two patients had M. tuberculosis isolates with a different drug-resistance pattern (pyrazinamide monoresistance) and lacked any clear epidemiologic links to the index patient or the other cases. All patients except the index patient's parent and young relative reported excessive alcohol use ( Table 2 ). The patients ranged in age from 15 to 47 years (median: 37.5 years). Five of the seven patients in this cluster who were eligible for DOT did not receive it consistently.
During the entire investigation, a total of 79 contacts of the eight patients in this cluster were identified. Fifty-one (65%) contacts were fully evaluated. Of these, two had a self-reported history of previous completion of TB treatment. Five (10%) of the 51 had a positive TST result and began therapy for latent TB infection. Of the 28 contacts who were not fully evaluated, 14 (50%) could not be located, 11 (39%) moved to another state, and three (11%) declined evaluation. No additional cases were identified.
As of February 2009, the index patient was clinically stable with negative AFB sputum smear and culture results and improvement noted on chest radiographs. The patient continues to receive MDR TB treatment by DOT. The patient will receive treatment through at least May 2009 to complete 18-24 months of appropriate TB therapy (5). The index patient's young relative with MDR TB and the remaining five patients in the cluster have all successfully completed TB treatment.
Editorial Note: Results of this cluster investigation revealed that at least four, and likely six, TB patients were involved in the same chain of transmission. These patients included the index patient, a young relative with MDR TB, the index patient's parent who died of TB meningitis, a known social contact, and two persons with unconfirmed social contact who frequented the same neighborhood. TB genotyping can help detect TB outbreaks earlier by highlighting unsuspected relationships among patients (6) . In this cluster, several patients were unwilling to name social contacts, and TB genotyping proved useful in establishing otherwise undisclosed relationships. The result of this more rigorous investigation demonstrated ongoing transmission among a larger group of patients than originally identified. However, although TB genotyping is useful in establishing connections between patients, it cannot be used without also pursuing epidemiologic links. Two of the eight patients described in this cluster probably were not part of the same transmission chain, based on having a unique DST pattern (resistance to pyrazinamide only) and no clear epidemiologic link to the other six patients in this cluster.
TB is a nationally notifiable infectious disease; successful treatment of TB benefits not only the individual but also the community (5) . In this outbreak, the index patient probably was contagious for >1,000 days. Multiple interrelated factors contributed to treatment interruptions and inconsistent DOT, including the index patient's excessive alcohol and illicit drug use and unstable housing arrangements and a general misunderstanding and mistrust among patients and their contacts of the health department's responsibility for TB patient care. DOT is a key component and an important example of the many measures used in patient-centered case management. DOT ensures a patient's adherence to treatment, prevents development of drug resistance, and should be considered for all TB patients (5) . The sufficiency of laws that authorize and support public health agencies' use of DOT and other roles in preventing the spread of TB can vary by jurisdiction (7). More recently, CDC and some of its public health partners have explored various approaches to strengthening public health agencies' legal preparedness for TB control and prevention. These approaches include 1) development of tools such as model legislative provisions that state policy makers and public health officials might use for examining existing laws regarding TB control, 2) table-top exercises for assessing understanding of jurisdiction-specific laws for TB control, and 3) informational guides, such as a handbook on TB control law, designed for public health practitioners and their legal counsel. This cluster also demonstrates the importance of TB contact investigations to prevent disease. A key challenge in the control of TB in the United States is conducting thorough investigations to protect the contacts of persons with infectious TB. Suboptimal contact investigations might occur when the persons with TB, such as those described in this report, are unable or unwilling to cooperate with the health department, or when public health resources for TB control measures are limited (2) . 
Simian Malaria in a U.S. TravelerNew York, 2008
Four species of intraerythrocytic protozoa of the genus Plasmodium (P. falciparum, P. vivax, P. ovale, and P. malariae) are known to cause malaria in humans. However, recent reports from Asia suggest the possibility that a fifth malaria species, Plasmodium knowlesi, is emerging as an important zoonotic human pathogen. Although more than 20 species of Plasmodium can infect nonhuman primates, until recently, naturally acquired human infections of simian malaria were viewed as rare events lacking public health significance. When viewed by light microscopy (the gold standard for laboratory diagnosis of malaria), many of the simian species are almost indistinguishable from the four Plasmodium species that cause infection in humans (Table) . Molecular techniques, such as polymerase chain reaction (PCR) amplification and microsatellite analysis, are needed for definitive species determination. This report describes the first recognized case of imported simian malaria in several decades in the United States, diagnosed in 2008 in a patient from New York who had traveled to the Philippines. Atypical features of the parasite seen on light microscopy triggered further molecular testing, which confirmed the diagnosis of P. knowlesi. To date, all simian malaria species have been susceptible to chloroquine treatment. Molecular analysis of certain malaria parasites isolated from ill travelers returning to the United States from Asia or South America can more accurately assess the burden of simian malaria parasite infections in humans.
The first recognized case of naturally acquired simian malaria was a 1965 case of P. knowlesi infection in an employee of the U.S. Army who had returned home from an assignment in Southeast Asia (1); subsequent reports were few and unconfirmed. In 2002, investigators in Malaysia noted an increasing number of P. malariae cases with atypical features, including increased clinical severity and higher parasitemia (2) . By using a nested PCR assay, more than 50% of these malaria cases were determined to be P. knowlesi; none were P. malariae, as originally determined by microscopy (2). In a retrospective evaluation by the same investigators during 2001-2006, 28% of 960 specimens from patients in Sarawak, Malaysian Borneo, were found to be P. knowlesi, after being morphologically diagnosed most often as P. malariae (3) . The group also reported four unusual fatalities attributed to severe malaria caused by P. malariae that was later confirmed as P. knowlesi by PCR. Additional cases of naturally occurring P. knowlesi infection in humans have been reported from Singapore (4), the Thai-Burma border (5), the Philippines (6), Yunnan Province in China (7), and Finland, where a returning traveler from
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Malaysia was misdiagnosed initially as having infection with P. falciparum (8) .
Case Report
In the recent U.S. case, a woman aged 50 years with no previous history of malaria who was born in the Philippines but had lived in the United States for 25 years, returned to her home country to visit friends and relatives on October 17, 2008. While there, she stayed on the island of Palawan in a cabin located at the edge of a forested area known to be a habitat for long-tailed macaques. She had not taken malaria chemoprophylaxis and had not used any mosquito-avoidance measures, both of which are recommended preventive measures for travelers to this area.
The woman returned to the United States on October 30, 2008, and noted the onset of a headache. Fever and chills ensued, and symptoms persisted for several days, after which she sought medical attention. In the emergency department, she was noted to be hypotensive and to have thrombocytopenia. Examination of thick and thin malaria smears (Figure 1) was ordered, and an initial, erroneous diagnosis of babesiosis was made by a laboratory technician. Upon review by the laboratory supervisor the following morning, the diagnosis was reassessed as malaria with 2.9% of red cells parasitized. However, the atypical appearance of the Plasmodium sp. seen in the smears prevented a species-specific diagnosis. The woman was treated successfully with atovaquone-proguanil and primaquine for Plasmodium of undetermined species.
An ethylenediaminetetraacetic acid (EDTA) blood tube and two stained smears were sent to New York state's Wadsworth Center Parasitology Reference Laboratory for confirmation of malaria and molecular determination of species by PCR. The Wadsworth Center confirmed the presence of atypical rings and schizonts of a Plasmodium species (Figure 1 ), but conventional PCR targeting the small subunit (SSU) of rRNA did not yield a product consistent with any of the four species of Plasmodium known to infect humans. The specimen also was negative for the variants of P. ovale, which are commonly seen in Southeast Asia. However, primers specific for the SSU rDNA of the genus Plasmodium yielded a 1,055-bp PCR product that was sequenced and noted to be a 99% match over its full length to the SSU rRNA gene from P. knowlesi (H strain) (9) . These data confirmed that the infection was caused by P. knowlesi. Editorial Note: Several conditions need to coincide for simian species of Plasmodium to infect humans: 1) human erythrocytes must be susceptible to invasion by simian parasites, 2) humans must be near or in forests where nonhuman simians are infected, and 3) anopheline mosquitoes that feed on both humans and nonhuman simians must be present (10) . Many areas in Asia and South America have overlapping populations of nonhuman primates that serve as reservoirs for simian malaria and competent Anopheles mosquito vectors that are necessary to transmit the infection to humans (Table, Figure 2) (1). For P. knowlesi in Asia, the normal hosts are long-tailed and pig-tailed macaques and mitered-leaf monkeys, which are found with Anopheles mosquito vectors of the Leucosphyrus group, enabling transmission of infection (1). Other simian malaria species known to infect humans include P. simium and P. brasilianum in South America and P. cynomolgi and P. inui in Asia (1,10). Most simian malaria infections in humans can cause mild or moderate disease but often are self-limited, not requiring antimalarial therapy (1). However, P. knowlesi, with its 24-hour asexual replication cycle, can result in large parasite burden and severe, life-threatening disease (3). Severe malaria imported from Asia should alert the physician to the possibility of infection with P. knowlesi. Health-care providers also should consider hospitalization if the patient with malaria reports travel to forested areas of Asia, where P. knowlesi transmission occurs. Simian Plasmodium species are susceptible to all available antimalarials in the United States. Although definitive diagnosis as a simian species of Plasmodium cannot be made in time to guide selection of antimalarials at the initiation of therapy, treatment for undetermined Plasmodium species will effectively treat all simian species. Use of current treatment and chemoprophylaxis guidelines are appropriate for treating and preventing simian malaria infections in humans.
Health-care providers of patients with malaria and laboratories that diagnose malaria imported from Asia or non-falciparum malaria from South America should refer appropriate specimens to a Clinical Laboratory Improvement Amendments (CLIA)-verified state health reference laboratory or CDC's Division of Parasitic Diseases Reference Laboratory for species confirmation by molecular testing. In the United States, approximately 1,500 malaria cases are reported each year, almost all imported from areas where malaria is endemic; approximately 200 of these cases are imported from Asia or South America. In the United States, the potential for not recognizing a Plasmodium infection of simian origin is high because diagnosis usually relies on microscopic examination of Giemsa-stained smears rather than diagnosis by molecular techniques. Only a few laboratories (including state and federal public health reference and commercial laboratories) routinely use molecular assays, and even fewer have the capacity to confirm simian species.
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United States
151 306 621 2,051 2,359 2,783 5,691 6,607 39,537 62,294 33 47 90 405 596 New England1 - American Samoa - 0 0 - - - 0 1 - 1 - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 1 15 - 5 - 0 0 - - Puerto- 0 0 - - - 0 1 - - - 0 0 - - South Dakota - 0 1 - 1 - 0 0 - - - 0 1 - 1 S. Atlantic1 - - - 0 2 - 5 - 0 2 - 1 District of Columbia U 0 0 U U U 0 0 U U - 0 2 - 23 - 0 2 - 3 Idaho § - 0 3 - 4 - 0 2 1 - - 0 1 - 1 Montana § - 0 1 2 - - 0 1 - - - 0 2 2 1 Nevada § - 0 3 2 - 1 0 3 6 7 - 0 2 3 2 New Mexico § - 0 3 1 3 - 0 2 3 2 - 0 2 - 2 Utah - 0 2 - 2 - 0 3 - 2 - 0 2 1 5 Wyoming § - 0 1 - 2 - 0 1 - - - 0 0 - - Pacific3 - 0 4 2 1 American Samoa - 0 0 - - - 0 0 - - N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto Rico - 0 2 1 4 - 0 4 - 12 - 0 1 - - U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - - C.N.- 0 3 1 - - 0 2 1 8 Kansas - 0 1 2 - - 0 2 1 - - 0 2 3 1 Minnesota - 5 218 4 - - 0 8 1 - 1 0 4 4 7 Missouri - 0 1 - - - 0 3 2 1 1 0 2 7 8 Nebraska § - 0 2 - - - 0 2 - 1 - 0 1 - 2 North Dakota - 0 1 - - - 0 0 - - - 0 1 - - South Dakota - 0 1 1 - - 0 0 - - - 0 1 - 1 S. Atlantic3 - 0 0 - - - 0 1 - - E.S. Central - 1 5 3 1 - 0 2 5 2 - 0 6 1 14 Alabama § - 0 2 - - - 0 1 1 1 - 0 2 - - Kentucky - 0 2 - - - 0 1 - 1 - 0 1 - 4 Mississippi - 0 1 - - - 0 1 - - - 0 2 - 3 Tennessee § - 0 3 3 1 - 0 2 4 - - 0 3 1 7 W.S. Central1 - - 0 1 - 2 - 0 1 2 3 Idaho § - 0 1 1 1 - 0 1 - - - 0 1 2 2 Montana § - 0 16 - - - 0 0 - - - 0 1 - 1 Nevada § - 0 2 - - - 0 0 - 3 - 0 1 2 1 New Mexico § - 0 2 - 1 - 0 1 - - - 0 1 - 3 Utah - 0 1 - - - 0 1 - - - 0 1 - 3 Wyoming § - 0 1 - - - 0 0 - - - 0 1 - 1 Pacific4 American Samoa N 0 0 N N - 0 0 - - - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 2 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 1 - - 0 1 - - U.S. Virgin Islands N 0 0 N N - 0 0 - - - 0 0 - -- 0 0 - - - 0 1 - 2 Oklahoma -3 - 0 0 - - - 0 1 - - Montana † - 0 11 3 15 - 0 3 4 - - 0 1 - - Nevada † - 0 7 5 1 - 0 4 - - - 0 2 - - New Mexico † - 1 8 7 4 - 0 3 5 6 - 0 1 - 1 Utah - 3 17 1 49 - 0 6 - - - 0 1 1 - Wyoming † - 0 2 - 3 - 0 4 6 1 - 0 2 - - Pacific1 - - Hawaii - 0 3 5 2 - 0 0 - - N 0 0 N N Oregon † - 3 15 30 21 - 0 2 - - - 0 1 - - Washington 4 6 77 16 13 - 0 0 - - - 0 0 - - American Samoa - 0 0 - - N 0 0 N N N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 0 - - N 0 0 N N Puerto Rico - 0 0 - - 2 1 5 8 7 N 0 0 N N U.S. Virgin Islands - 0 0 - - N 0 0 N N N 0N 0 0 N N - 0 0 - - Washington N 0 0 N N - 0 0 - - American Samoa - 0 12 - - - 0 0 - - C.N.M.I. - - - - - - - - - - Guam - 0 0 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 0 - - U.S. Virgin Islands - 0 0 - - - 0 0 - - C.N.- 0 0 - - - 0 0 - - - 0 2 2 1 North Dakota - 0 0 - - - 0 0 - - - 0 0 - - South Dakota - 0 1 - 1 - 0 1 - 1 - 0 1 - - S. Atlantic
